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Abstract. Fructose-rich diet induces metabolic chan-
ges similar to those observed in metabolic syndrome. 
Among other matrix metalloproteinases, MMP-9 has 
an important role in adverse cardiac remodelling 
and might have a role in the development of cardio-
vascular disorders associated with metabolic syn-
drome. The changes of MMP-9 expression could be 
mediated via the NFκB pathway. In this study we 
investigated the effect of fructose-rich diet on MMP-9 
expression in the heart of male and female rats, along 
with the effect of fructose-rich diet and oestradiol on 
MMP-9 expression in ovariectomized fema les. We 
further assessed the effect of fructose-rich diet and 
oestradiol on NFκB activation, measured as the level 
of p65 phosphorylation at Ser 276. The results showed 
that the diet regime did not affect the heart mass. 
Higher MMP-9 gene expression was found in cardiac 
tissue of male rats fed the fructose-rich diet than in 
females on the same diet regime. In ovariectomized 
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females, fructose-rich diet upregula ted MMP-9 pro-
tein and mRNA expression in the heart, as well as 
phosphorylation of the p65 subunit of NFκB at Ser 
276. Oestradiol replacement therapy reverted these 
changes in the heart of ovariectomized females. This 
study has shown that oestradiol could revert the ear-
ly molecular changes in MMP-9 expression induced 
by fructose-rich diet that occurred before cardiac 
hypertrophy development by decreasing phospho-
rylation of the NFκB p65 subunit at Ser 276. 
Introduction
Metabolic	syndrome	is	described	as	a	pro-inflamma-
tory condition associated with increased risk for diabe-
tes, accelerated atherosclerosis and increased incidence 
of	cardiovascular	diseases	(Isomaa	et	al.,	2001;	Grundy	
et	al.,	2004;	Paoletti	et	al.,	2006).	 It	combines	several	
risk	 factors	 for	cardiovascular	disease	occurrence:	hy-
pertension, insulin resistance, hyperinsulinaemia, dys-
lipidaemia	 and	 abdominal	 obesity	 (Eckel	 et	 al.,	 2005;	
Grundy,	2007).	Numerous	experiments	on	animals	and	
human	demonstrated	that	fructose-rich	diet	(FRD)	might	
induce metabolic changes similar to those observed in 
metabolic	syndrome	(Dai	and	McNeil,	1995;	Sharabi	et	
al.,	 2007;	 Orron-Herman	 et	 al.,	 2008;	Axelsen	 et	 al.,	
2010;	Dekker	et	al.,	2010;	Tappy	and	Le,	2010).	
Recently,	it	was	suggested	that	matrix	metalloprotein-
ases	(MMPs)	might	have	a	role	in	the	development	of	
cardiovascular disorders associated with metabolic syn-
drome	(Cicero	et	al.,	2007;	Miksztowich	et	al.,	2008).	
MMPs are calcium-dependent, zinc-containing endo-
peptidases,	which	 are	 involved	 in	 extracellular	matrix	
(ECM)	remodelling	(Bode	and	Maskos,	2003;	Visse	and	
Nagase,	2003).	Knowing	that	adverse	ECM	remodelling	
of the myocardium and vasculature leads to the develop-
ment of cardiovascular disorders, it is not surprising that 
MMPs represent an important biological components in 
the	 myocardium	 (Spinale,	 2002;	 Lopes	 et	 al.,	 2004;	
Newby,	2005).
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MMP-9	 or	 gelatinase	 B,	 which	 is	 an	 inducible	 en-
zyme	tearing	down	type	IV	collagen	(Gioia	et	al.,	2009),	
has been shown to play an important role in the patho-
genesis of a wide spectrum of cardiovascular disorders 
(Dollery	et	al.,	1995;	Lindsay	et	al.,	2002).	An	elevated	
level	 of	MMP-9	 represents	 one	of	 the	 risk	 factors	 for	
development of cardiovascular diseases and myocardial 
infarction	(Ferroni	et	al.,	2003).	An	increasing	circulat-
ing	MMP-9	level	and	activity	was	found	in	patients	with	
metabolic	syndrome	(Cicero	et	al.,	2007;	Goncalves	et	
al,	2009),	hyperglycaemia	(Lee	et	al.,	2005),	and	type	2	
diabetes	mellitus	(Uemura	et	al.,	2001).	Previous	studies	
have	shown	that	FRD	enhanced	MMP-9	activity	in	rat	
smooth	muscle	 cells	 (Lu	 et	 al.,	 2013),	 as	 well	 as	 the	
MMP-9	protein	level	in	aortic	tissue	of	ApoE-KO	mice	
(Cannizzo	et	al.,	2012).	As	far	as	we	know,	there	are	no	
experimental	studies	investigating	the	effects	of	FRD	on	
MMP-9	 expression	 in	 the	 heart.	 Because	MMP-9	 ex-
pression shows gender differences with higher levels 
detected	in	male	rats	(Woodrum	et	al.,	2005),	we	consid-
ered	interesting	to	examine	whether	FRD	affects	MMP-9	
expression	in	a	gender-specific	manner	and	to	evaluate	
the	 influence	 of	 female	 sex	 hormones	 on	MMP-9	 ex-
pression	in	the	context	of	fructose-rich	diet.
The	changes	of	MMP-9	expression	could	be	mediated	
via	the	nuclear	factor	κ-light-chain-enhancer	of	activat-
ed	B	cells	(NFκB)	pathway	(Guo	et	al.,	2008).	NFκB	is	
activated	through	phosphorylation	of	the	p65	subunit	at	
Ser	276	(Kim	et	al.,	2012).	Therefore,	we	hypothesized	
that	phosphorylation	of	the	p65	subunit	at	Ser	276	could	
be	implicated	in	the	induction	of	MMP-9	expression.
The purpose of this study was to investigate the effect 
of	FRD	on	MMP-9	expression	in	the	heart	of	male	and	
female rats and to evaluate the effect of oestrogen on 
MMP-9	expression	in	fructose-fed	rats.	We	further	as-
sessed	 the	 effect	 of	 FRD	 and	 17β-oestradiol	 (E2)	 on	
NFκB	activation,	measured	as	the	level	of	p65	phospho-
rylation	at	Ser	276.
Material and Methods
Chemicals
We	purchased	fructose	from	API-PEK	(Becej,	Serbia).	
Anti-NFκB	p65	(phospho	S276)	and	anti-MMP-9	anti-
bodies	were	 obtained	 from	Abcam	 (Cambridge,	 UK).	
Secondary anti-rabbit antibody was the product of Santa 
Cruz	Biotechnology	 (Santa	Cruz,	CA).	 17β-oestradiol	
(E2)	 was	 purchased	 from	 Sigma-Aldrich	 Corporation	
(St.	Louis,	MO).
Animals
This	 research	 was	 approved	 by	 the	 official	 Vinca	
Institute’s	Ethical	Committee	for	Experimental	Animals	
and	 conformed	 to	 the	 Directive	 2010/63/EU	 of	 the	
European Parliament. Twenty-one-day-old male and fe-
male Wistar rats were separated from their mothers. 
Rats were bred at the Animal Facility of Vinca Institute 
of Nuclear Sciences. Male rats were divided into a nor-
mal	diet	(ND-male)	and	a	fructose-fed	group	(FRD-male).	
Females were divided into an intact and an ovariecto-
mized group. Intact females were further divided into a 
normal	diet	(ND-female)	and	a	fructose-rich	diet	(FRD-
female)	 group.	 Ovariectomized	 females	 were	 divided	
into	a	normal	diet	group	(ND-OVX),	a	fructose-rich	diet	
group	 (FRD-OVX)	 and	 animals	 fed	 the	 fructose-rich	
diet and subjected to oestradiol replacement therapy 
(FRD-OVX+E2).	Animals	held	on	normal	diet	had	free	
access to tap water and normal laboratory chow. Animals 
fed the fructose-rich diet also had standard laboratory 
chow,	while	 10%	 (w/v)	 fructose	 solution	 replaced	 the	
tap water. This diet regime lasted for nine weeks. In the 
ovariectomized group, ovariectomy was performed two 
weeks	before	sacrifice	under	ketamine	(40	mg/kg,	intra-
peritoneally)	–	xylazine	(5	mg/kg,	 intraperitonelly)	
anaesthesia.	 E2	 replacement	 therapy	 (40	μg/kg,	 sub-
cutaneously, every second day to achieve concentration 
near	the	physiological	level)	started	a	day	after	ovariec-
tomy	and	continued	until	the	day	before	sacrifice	(Sales	
et	al.,	2010).	This	duration	of	E2	replacement	 therapy	
was	shown	to	allow	E2	to	achieve	 long-term	genomic	
effects,	 but	 is	 also	 sufficient	 for	 E2	 to	 influence	 non-
genomic signalling mechanisms (Ko ricanac et al., 
2009).	In	order	 to	avoid	the	effects	of	 injection	stress,	
ND-OVX and FRD-OVX animals were injected with 
vehicle	(linseed	oil).	Each	experimental	group	contained	
nine	 animals	 (N	=	 9),	which	means	 that	 a	 total	 of	 63	
animals	participated	in	the	experiment.
Measurement of body mass and mass of heart
Body	mass	was	measured	 at	 the	 end	 of	 the	 experi-
ment. Heart mass was determined immediately after 
killing	the	animals.	The	hearts	were	excised,	washed	in	
saline and dried before the measurement.
Tissue homogenization and Western blot
Heart	 tissue	was	 homogenized	with	 an	Ultra-turrax	
homogenizer	 in	 homogenization	 buffer	 (pH	 7.4;	 con-
taining:	 10	mM	Tris,	 150	mM	NaCl,	 1	mM	EGTA,	
1%	Triton	X-100,	protease	inhibitors	–	2	mM	PMSF,	
10	μg/ml	leupeptin,	and	10	μg/ml	aprotinin	and	phos-
phatase inhibitors – 1 mM Na
3
VO
4
	 and	 10	mM	NaF)	
and	homogenates	were	centrifuged	at	600	g	for	20	min.	
The supernatants were further ultracentrifuged at 
100,000 g	for	60	min.	To	determine	the	protein	concen-
tration we used the BCA method. After boiling in 
Laemmli sample buffer, supernatants were used for Wes-
tern	blot	analysis.	Equal	amounts	of	proteins	(100	μg/
lane)	were	fractioned	by	10%	SDS	polyacrylamide	gels	
and transferred onto PVDF membranes. Membranes 
were	blocked	with	5%	bovine	serum	albumin	for	2	h	
at room temperature, after which they were incubated 
with	 primary	 antibodies	 MMP-9	 (ab7299,	 dilution	
1 : 500)	and	NFκB	p65	(Phospho	S276)	(ab30632,	dilu-
tion	1 : 1000)	overnight	at	4	°C.	Membranes	were	subse-
quently	washed	and	incubated	with	peroxidase-labelled	
secondary anti-rabbit antibody for two hours at room 
temperature. Signals were detected with ECL reagents. 
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All	Western	blot	experiments	were	performed	in	tripli-
cates. To assess the equal protein loading, we used 
β-actin	as	a	 loading	control.	We	optimized	 the	protein	
quantity, primary and secondary antibody concentra-
tions, and conditions of signal development in order to 
avoid ECL signal saturation. Films were scanned and 
intensities were determined using ImageJ software (NIH, 
Bethesda,	MD).	
RNA isolation and expression by real-time 
polymerase chain reaction
Total	RNA	was	extracted	from	the	heart	tissue	using	
Trizol	reagent	(Ambion	Inc.,	Austin,	TX)	according	to	
the protocol recommended by the manufacturer. The 
quantity of RNA was assessed spectrophotometrically 
(NanoDrop®	 ND-1000,	 Thermo	 Scientific,	 Rockford,	
IL).	 In	 order	 to	 eliminate	 the	 possible	 contamination	
with	 genomic	 DNA,	 purified	 RNA	 was	 treated	 with	
DNAse	I.	First	strand	cDNAs	were	generated	from	2	μg	
of total pure RNA and First Strand cDNA Synthesis kit, 
with	 oligodT18	 primers,	 according	 to	 manufacturer’s	
instructions	 (Fermentas,	Vilnius,	 Lithuania).	Quan	tita-
tive	 real-time	 PCR	 (Q-PCR)	 amplification	 was	 per-
formed	in	duplicate	using	the	ABI	Real-time	7500	sys-
tem	 (ABI,	 Foster	 City,	 CA).	 The	 relative	 levels	 of	
spe	cific	MMP-9	mRNA	in	 the	heart	were	assessed	by	
amplification	in	a	total	volume	of	25	μl	by	pre-developed	
TaqMan®	 Gene	 Expression	 Assays	 Rn00579162_m1.	
18s	 rRNA	 was	 used	 as	 an	 internal	 reference	 (Gene	
Expression	 Assays	 ID	 Hs99999901_s1).	 Cycling	 pa-
rameters	were	as	follows:	initial	denaturation	at	95	°C	
for	10	min,	followed	by	40	cycles	of	a	denaturation	step	
at	95	°C	for	15	s,	and	an	annealing	step	at	60	°C	for	60	s.	
In order to process the data and compare the differences 
in	relative	gene	expression	between	groups	we	used	the	
2-ΔCt method. The calculated Ct values	for	MMP-9	in	re-
sponse to various treatments were normalized to the re-
spective Ct values	for	18S	rRNA.
Statistical analysis
Data were analysed using the GraphPad Prism 5 sta-
tistical	package	(San	Diego,	CA).	All	data	are	expressed	
as	mean	±	standard	deviation,	for	nine	animals	per	each	
experimental	group.	Values	of	continuous	variables	with	
skewed distribution were compared by the nonparamet-
ric	Mann-Whitney	U	test,	which	was	used	to	examine	
the	statistical	significance	among	experimental	groups.	
The	 differences	 in	 relative	 gene	 expression	 between	
groups	were	calculated	using	2-ΔCt methods (Livak and 
Schmittgen,	2001).	Values	of	P	<	0.05	were	considered	
statistically	significant.
Results
Body	mass	between	female	and	male	rats	was	signifi-
cantly different in both, ND and FRD group (P < 0.001, 
ND Female vs.	 ND	Male;	 P	 <	 0.05,	 FRD	Female	 vs. 
FRD	Male)	(Table	1).	In	males,	FRD	did	not	alter	 the	
body mass, while in females FRD increased the body 
mass (P < 0.05, ND Female vs.	FRD	Female).	The	mass	
of the heart was not affected by the diet regime regard-
less	of	sex.	Males	that	were	fed	normal	diet	had	signifi-
cantly higher mass of the heart than females on the same 
diet regime (P < 0.01, ND Female vs.	ND	Male).	The	
heart-to-body ratio did not differ among the groups.
To	examine	the	effect	of	FRD	on	MMP9 gene	expres-
sion we performed quantitative RT-PCR analysis. The re-
sults showed higher MMP9	gene	expression	in	FRD-male	
compared to the FRD-female group (P < 0.01, FRD 
Female	vs.	FRD	Male)	(Fig.	1a).	FRD	did	not	change	
MMP9	gene	expression	in	females.	In	males,	FRD	up-
regulated MMP9	expression,	but	this	showed	not	to	be	
statistically	 significant.	 The	 fact	 that	 the	MMP9 gene 
showed	higher	 expression	 in	FRD-males	 compared	 to	
FRD-females made us to focus on the role of oestradiol 
in the regulation of MMP9	 expression	 in	 the	 heart	 of	
fructose-fed rats.
We therefore compared the effects of FRD and subse-
quent oestradiol treatment on ovariectomized female rats. 
In ovariectomized females, FRD upregulated MMP9 
gene	expression	(P	<	0.01,	ND-OVX	vs.	FRD-OVX).	In	
contrast,	E2	replacement	therapy	significantly	down-re-
gulated MMP9	gene	expression	in	fructose-fed	ovariec-
tomized animals (P < 0.01, FRD-OVX vs.	FRD-OVX+E2)	
and decreased it even below the level detected in ND ova-
riectomized females (P < 0.01, ND-OVX vs.	FRD-OVX)	
(Fig.	1b).
As	presented	in	Table	2,	neither	FRD	nor	E2	replace-
ment therapy affected body mass or the mass of the heart. 
This showed that heart hypertrophy had not yet occurred. 
To	 (semi)quantitatively	 assay	 the	 MMP-9	 protein	
level	in	the	context	of	FRD	and	subsequent	E2	replace-
ment therapy, we performed Western blot analysis. 
These	results	are	presented	in	Fig.	2.	Similarly	as	for	the	
mRNA	 level,	FRD	significantly	 increased	 the	MMP-9	
Fructose-Rich	Diet	and	Oestradiol	Affect	MMP-9	Expression
Table 1. Body mass and the mass of the heart of intact females and males
ND Female FRD Female ND Male FRD Male
Body mass (g) 263.20	±	30.26 279.50	±	20.52* 338.90	±	40.45# 311.30	±	37.58$
Mass of the heart (g) 0.83	±	0.13 0.83	±	0.08 1.05	±	0.14** 0.94	±	0.16
Heart to body ratio (×10–3) 3.17	±	0.16 3.04	±	0.21 3.11	±	0.19 3.00	±	0.26
Values	are	expressed	as	means	±	standard	deviations	for	a	total	of	9	rats	in	each	experimental	group.	Mann-Whitney	U	test	was	used	to	
compare	the	values	of	skewed	continuous	variables	between	groups;	in	all	tests,	P	values	<	0.05	were	considered	statistically	signifi-
cant. ND – normal diet, FRD – fructose-rich diet. *P < 0.05 ND Female vs. FRD Female, #P < 0.001 ND Female vs. ND Male, $P < 0.05 
FRD Female vs. FRD Male, **P < 0.01 ND Male vs. ND Female.
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before cardiac structural changes have been detected. 
This	change	in	MMP-9	expression	is	oestrogen	depend-
ent and is in line with increased phosphorylation of the 
p65	subunit	of	NFκB	transcription	factor,	which	occurs	
during the FRD regime.
The	results	showed	that	9-week	treatment	with	10%	
fructose solution did not cause any changes in the mass 
of the heart. This indicated that heart hypertrophy had 
not yet developed. Other studies demonstrated that ei-
ther increased concentration of the consumed fructose 
or prolonged period of the diet regime leads to develop-
ment	of	cardiac	hypertrophy,	excessive	collagen	deposi-
tion and increased stiffness of the left ventricle (Koba-
yashi	et	al.,	1993;	Kamide	et	al.,	2002;	Patel	et	al.,	2009).	
Previously,	we	have	reported	that	10%	fructose-rich	
diet	regime	in	the	duration	of	9	weeks	leads	to	develop-
ment	of	cardiac	insulin	resistance	(Zakula	et	al.,	2011;	
Romic	et	al.,	2013).	We	also	reported	that	FRD	signifi-
cantly elevated blood pressure in male rats, while in fe-
males we did not observe any differences in blood pres-
sure	as	a	consequence	of	FRD	(Koricanac	et	al.,	2013).	
Fig. 1. Relative MMP9	gene	expression.
The	cDNAs	from	heart	tissue	specimens	were	used	as	templates	in	RT-qPCR	for	relative	quantification	of	MMP-9	mRNA	
expression.	For	each	specimen,	 the	expression	level	of	MMP-9	mRNA	was	normalized	 to	 the	housekeeping	gene	18S	
rRNA.	Relative	expression	of	MMP-9,	normalized	against	the	housekeeping	gene,	was	calculated	using	the	comparative	
Ct method. (a)	Relative	MMP9	gene	expression	in	male	and	female	rats	fed	a	standard	laboratory	food	and	fructose-rich	
diet. Males on fructose-rich diet showed higher MMP9	gene	expression	than	females	on	the	same	diet.	ND	–	normal	diet,	
FRD	–	fructose-rich	diet,	**	P	<	0.01.	(b)	Relative	MMP9	gene	expression	in	ovariectomized	fructose-fed	rats	with	or	
without	oestradiol	replacement.	OVX	–	ovariectomy,	E2	–	oestradiol	treatment,	**	P	<	0.01.
Table 2. Body mass and the mass of the heart of ovariectomized rats
ND-OVX FRD-OVX FRD-OVX+E2
Body mass (g) 293.20	±	23.09 286.70	±	23.87 280.60	±	18.15
Mass of the heart (g) 0.85	±	0.08 0.84	±	0.10 0.84	±	0.07
Heart to body ratio (×10–3) 2.92	±	0.13 3.00	±0.14 2.98	±	0.15
Data	presented	are	means	±	standard	deviations	for	9	rats	per	each	experimental	group.	Mann-Whitney	U	test	was	used	to	compare	the	
values	of	skewed	continuous	variables	between	groups;	in	all	tests,	P	values	<	0.05	were	considered	statistically	significant.	None	of	
the	comparisons	showed	statistical	significance.	FRD	and	E2	replacement	therapy	did	not	affect	body	mass	and	the	mass	of	the	heart.	
ND	–	normal	diet,	FRD	–	fructose-rich	diet,	OVX	–	ovariectomized,	E2	–	oestradiol	treatment.
protein level in the heart of ovariectomized rats (P < 
0.001, ND-OVX vs.	FRD-OVX).	In	contrast,	oestradiol	
treatment	significantly	decreased	MMP-9	protein	expres-
sion compared to both, FRD-OVX (P < 0.01, FRD-OVX 
vs.	FRD-OVX+E2)	and	ND-OVX	animals	(P	<	0.001,	
ND-OVX vs.	FRD-OVX+E2).
Having	in	mind	that	NFκB	regulates	MMP-9	expres-
sion,	we	investigated	the	effect	of	FRD	and	E2	(in	the	
context	 of	FRD)	on	 activation	 of	 this	 transcription	
factor.	As	 it	 was	 presented	 in	 Fig.	 3,	 FRD	 increased	
phosphorylation	of	the	p65	subunit	at	Ser	276	(P	<	0.01,	
ND-OVX vs.	 FRD-OVX),	 thereby	 activating	 NFκB,	
while	E2	replacement	therapy	reduced	p65	phosphoryl-
ation (P < 0.05, FRD-OVX vs.	FRD-OVX+E2)	and	de-
creased it to the level below that detected in ND-OVX 
females (P < 0.01, ND-OVX vs.	FRD-OVX+E2).	
Discussion
The	major	finding	of	this	study	is	that	FRD	increases	
MMP-9	expression	in	ovariectomized	female	rats	even	
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able to protect rats from changes in the MMP9	gene	ex-
pression that are consequences of FRD. As a further 
confirmation	of	this	protective	effect	of	E2	in	the	con-
text	of	FRD,	beside	results	obtained	at	 the	gene	 level,	
we	have	also	studied	the	MMP-9	changes	at	the	protein	
level.	Changes	in	the	MMP-9	protein	level	were	in	the	
same	direction	as	 those	observed	 for	gene	expression,	
except	that	E2	decreased	the	MMP-9	protein	level	even	
below	the	level	detected	in	ND-OVX	animals.	MMP-9	
is a key contributor to adverse myocardial remodelling. 
Because	 the	 cellular	 source	 of	MMP-9	 appears	 to	 be	
predominantly	 infiltrating	 inflammatory	 cells	 (Mukhe-
riee	et	al.,	2006),	 it	 is	not	surprising	 that	 inhibition	of	
MMP-9	expression	or	 activity	 reduced	myocardial	 in-
flammation	and	remodelling	(Spinale,	2007).	Based	on	
the	aforementioned	findings,	we	can	conclude	that	FRD	
causes	 changes	 in	MMP-9	 expression	 in	 the	 rat	 heart	
even before structural changes have occurred, and that 
these	 early	molecular	 changes	 are	 reversible	with	E2.	
This	suggests	that	E2	could	protect	the	heart	from	pos-
sible harmful effects of FRD. 
Angiotensin II was shown to promote cardiovascular 
remodelling	through	the	increase	of	MMP-9	expression	
via	AT1R,	while	telmisartan	(AT1R	blocker)	and	capto-
pril	(angiotensin-converting	enzyme	inhibitor)	suppress	
MMP-9	 expression	 and	 activities	 (Okada	 et	 al.,	 2008,	
Adverse	ECM	remodelling	in	the	myocardium	finally	
results in mortality and morbidity associated with vari-
ous cardiovascular diseases including hypertension, 
myocardial	infarction,	cardiomyopathy,	and	finally	heart	
failure	(Cohn	et	al.,	2000).	MMPs	are	proposed	to	lead	
toward	LV	dilatation	and	heart	failure.	The	MMP-9	pro-
tein	level	and	activity	were	significantly	elevated	in	the	
spontaneously	 hypertensive	 heart	 failure	 (SHHF)	 rat	
model	(Li	et	al.,	2000).	The	results	of	other	studies	also	
indicate	that	MMP-9	has	an	important	role	in	the	cardiac	
remodelling associated with hypertension (Tayebjee et 
al.,	2004;	Chiao	et	al.,	2012).	MMP-9	directly	promotes	
myofibrilar	transformation	(Jiang	et	al.,	2013),	which	is	
important	 in	 the	 development	 of	 cardiac	 fibrosis	 and	
scar	formation	(Porter	and	Turner,	2009).	
In the presented study we detected elevated MMP9 
gene	expression	in	FRD-male	rats	compared	to	FRD-fe-
males. Further, we found that FRD upregulated MMP9 
gene	expression	in	ovariectomized	females.	A	previous	
study	 showed	 increased	 MMP-9	 activity	 in	 intimal	
smooth	muscle	cells	of	fructose-fed	rats	(Lu	et	al.,	2013).	
Be	cause	E2	could	reduce	MMP-9	expression	(Vegeto	et	
al.,	 2001),	 we	 have	 further	 investigated	 whether	 E2	
could revert changes in MMP9	gene	expression	induced	
by	FRD.	 Indeed,	we	showed	 that	E2	replacement	was	
able	 to	 revert	 these	 changes.	This	 confirms	 that	E2	 is	
Fig. 2.	MMP-9	protein	expression	in	ovariectomized	fruct-
ose-fed rats, rats with or without oestradiol treatment. 
Fructose-rich	 diet	 increased	 MMP-9	 protein	 expression,	
while oestradiol replacement therapy reverted this change 
and	decreased	MMP-9	expression	even	below	the	level	de-
tected in animals on normal diet. ND – normal diet, FRD 
–	fructose-rich	diet,	OVX	–	ovariectomy,	E2	–	oestradiol	
treatment,	**P	<	0.01,	***P	<	0.001.
Fig. 3. Effects of fructose-rich diet and oestradiol on phos-
phorylation	of	NFκB	p65	subunit	at	Ser	276. Fructose-rich 
diet	increased	phosphorylation	of	p65	subunit	at	Ser	276,	
thereby	 activating	 NFκB,	 while	 E2	 replacement	 therapy	
reduced	p65	phosphorylation.	ND	–	normal	 diet,	 FRD	–	
fructose-rich	 diet,	 OVX	 –	 ovariectomy,	 E2	 –	 oestradiol	
treatment,	*P	<	0.05,	**P	<	0.01.
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2009,	2010).	Several	studies	have	confirmed	that	NFκB	
is absolutely required and the most important transcrip-
tion	 factor	 for	MMP-9	production	 (Bond	 et	 al.,	 1998,	
2001;	Moon	et	al.,	2004).	In	various	cell	types,	angio-
tensin	II	activates	NFκB	(Marui	et	al.,	1993;	Kranzhofer	
et	al.,	1999),	and	MMP-9	expression	is	mediated	via	this	
signalling	pathway	(Guo	et	al.,	2008).	NFκB	activation	
could occur through phosphorylation and subsequent 
proteolytic	degradation	of	inhibitory	protein	IκB	(Ruiz-
Ortega	et	al.,	2006),	but	it	was	shown	that	there	is	weak	
degradation	of	IκB	in	response	to	angiotensin	II,	partic-
ularly	in	induction	of	MMP	expression	(Browatzaki	et	
al.,	 2005).	Alternatively,	 angiotensin	 II	 could	 activate	
NFκB	through	phosphorylation	of	the	p65	subunit	at	Ser	
276	via	AT1R	(Kim	et	al.,	2012).	
Our	 previous	 study	 (Bundalo	 et	 al.,	 2015)	 demon-
strated	that	FRD	increased	AT1R	and	ACE	expression	in	
ovariectomized rats and that oestradiol was able to re-
vert these changes. Interestingly, in this study we dem-
onstrated	that	the	pattern	of	changes	in	MMP-9	expres-
sion due to FRD and oestradiol treatment is similar to 
those	previously	reported	for	AT1R	and	ACE	expression	
(Bundalo	 et	 al.,	 2015).	 Considering	 previously	 men-
tioned	facts	(Marui	et	al.,	1993;	Kranzhofer	et	al.,	1999;	
Bond	et	al.,	2001;	Moon	et	al.,	2004;	Guo	et	al.,	2008;	
Okada	et	al.,	2008,	2009,	2010),	we	found	interesting	to	
investigate	changes	in	p65	phosphorylation	at	Ser	276	
under	the	influence	of	FRD,	and	subsequent	oestradiol	
treatment	in	the	context	of	FRD.	The	results	showed	that	
FRD	increased	p65	phosphorylation,	thereby	activating	
NFκB,	while	E2	replacement	therapy	restored	the	initial	
level	of	phosphorylation	 in	p65.	A	previous	study	 im-
plied	that	E2	inhibits	NFκB	activation	by	enhancing	the	
inhibitor	kBα	(IkBα)	kinase	level	and/or	by	stabilization	
of	IκBα	(by	decreasing	its	phosphorylation)	(Wen	et	al.,	
2004;	Xing	et	al.,	2012).	This	is	the	first	study	demon-
strating	 that	 E2	 decreases	 phosphorylation	 of	 the	 p65	
subunit	of	NFκB	at	Ser	276.	NFκB	plays	a	fundamental	
role	in	pathogenesis	of	insulin	resistance	and	type	2	dia-
betes	mellitus.	Taking	 into	 account	 that	NFκB,	beside	
MMP-9,	also	controls	many	pro-inflammatory	genes	in-
cluding	cytokines	(such	as	TNF-α,	IL-6	and	IL-8),	ad-
hesion	 molecules	 and	 chemokines	 (Cai	 et	 al.,	 2005;	
Shoelson	et	al.,	2006;	Wei	et	al.,	2008),	it	is	obvious	that	
E2,	by	decreasing	NFκB	activation,	displays	its	protec-
tive effect on the development of FRD-induced heart 
disorders.	This	 effect	 of	 E2	 on	NFκB	 activation	 is	 in	
accordance with our previous study that demonstrates 
that	E2	shows	a	protective	effect	on	the	development	of	
cardiac insulin resistance in fructose-fed rats (Romic et 
al.,	2013).	
The	pattern	of	changes	in	p65	phosphorylation	is	sim-
ilar	 to	 that	obtained	 for	MMP-9	under	 the	same	 treat-
ment.	Our	experiment	demonstrated	that	early	molecu-
lar	 changes	 in	 FRD-treated	 rats	 include	 elevated	 p65	
phosphorylation	at	Ser	276,	possibly	as	a	 result	of	 in-
creased	 AT1R	 expression.	 This	 phosphorylation	 acti-
vates	 NFκB,	 which	 consequently	 induces	 enhanced	
MMP-9	expression.	Further	studies	are	required	to	un-
equivocally	confirm	this	signalling	pathway.	Should	this	
diet regime be prolonged, the changes at the molecular 
level might promote adverse cardiovascular remodel-
ling, which could result in development of various car-
diovascular disorders. Obviously, this is the key point 
where changes at the molecular level have occurred but 
cardiac impairment has not yet emerged. An interesting 
finding	was	that	the	increase	in	MMP-9	expression	and	
NFκB	activation	that	occurred	as	a	result	of	FRD	was	
reversible	with	E2.	This	implicates	that	E2	shows	a	pro-
tective effect on the rat cardiac tissue by reducing the 
possibility of adverse ECM remodelling in the myocar-
dium, which may be a result of the harmful effect of 
FRD.
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